| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | AA-COCF3 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.038 | 0.4 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.049 | 0.4 |